Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Diabetes, Diabetic Foot Ulcer, Non-healing Wound
Interventions: ExpressGraft-C9T1 Skin Tissue; Biological
Lead sponsor: Stratatech, a Mallinckrodt Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Phoenix, Arizona • Fresno, California • San Francisco, California + 1 more

Conditions: Hypertension (HTN)
Interventions: Firibastat (QGC001) Period 1; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: Healthy Lifestyle
Interventions: Cooling Vest Procedure, Fasting overnight; Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 28 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Tolerance
Interventions: Ketone- Promoting Food Ingredient #1, Ketone- Promoting Food Ingredient #2, Ketone Free Placebo; Other
Lead sponsor: BHB Therapeutics, Ireland LTD; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Cerebral Palsy Children, Motor Disabilities, Developmental Disability, Rehabilitation, Early Intervention, Assistive Technology
Interventions: Therapist Training on Powered Mobility Implementation, Powered Mobility Intervention for Child-Caregiver Dyads; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 12 Months and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Hillsboro, Oregon • Portland, Oregon

Conditions: Denture Retention
Interventions: Investigational denture adhesive cream, Super Poligrip Free; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Gaucher Disease, Gaucher Disease, Type 1
Interventions: LY3884961; Genetic
Lead sponsor: Prevail Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 2
States / cities: Durham, North Carolina • Fairfax, Virginia

Conditions: Pain
Interventions: Advil PM Liqui-Gels Minis, Advil PM Liqui-Gels; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Lymphoblastic Leukemia
Interventions: Prednisone, Vincristine, Doxorubicin, PEG-asparaginase, Cytarabine, Methotrexate, Imatinib, Clofarabine, 6 Mercaptopurine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 51 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Malaria
Interventions: Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®); Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Infant, Extremely Premature, Length of Stay, Feeding
Interventions: NTrainer® Intervention, Control Intervention; Device
Lead sponsor: KC BioMediX, Inc; Industry
Eligibility: 26 Weeks to 31 Weeks
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 5
States / cities: San Jose, California • The Bronx, New York • Fort Worth, Texas + 1 more

Conditions: Age-Related Lung Function Decline
Interventions: Fisetin, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pharmacogenomic Drug Interaction
Interventions: Panel-based pharmacogenetic genotyping; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 40 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Risk Factor
Interventions: Experimental Intervention (MI-PrEP), Enhanced Treatment as Usual (E-TAU); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute Chest Syndrome, Sickle Cell Disease
Interventions: Unfractionated heparin; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer, Metastatic
Interventions: Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Visual Acuity
Interventions: etafilcon A investigational cosmetic lens 1, etafilcon A investigational cosmetic lens 2; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Tyler, Texas

Conditions: Postpartum Depression
Interventions: Interpersonal therapy-based treatment; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 12 Years to 19 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Healthy
Interventions: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2, Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3, Duragesic 25 mcg/h + Clinical Procedure 1, Duragesic 25 mcg/h + Clinical Procedure 2, Duragesic 25 mcg/h + Clinical Procedure 3; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Patent Ductus Arteriosus After Premature Birth
Interventions: Ibuprofen; Drug
Lead sponsor: IWK Health Centre; Other
Eligibility: Up to 72 Hours
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Orange, California • San Diego, California • Oklahoma City, Oklahoma

Conditions: Basic Motor Learning Problem
Interventions: Attentional prime, Sham prime; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Cognitive Performance
Interventions: TP1, TP2, Placebo; Other
Lead sponsor: Liquid I.V.; Other
Eligibility: 18 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Epilepsy Intractable
Interventions: Self-navigation task, Observation task; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronavirus, Vaccine Refusal
Interventions: Increasing Willingness and Uptake of COVID-19 Vaccination; Behavioral
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

BATokines as Biomarkers of Brown Fat in Humans

Tolerance and Safety of a Ketone-Promoting Food Ingredient

Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy

A Clinical Study to Assess Force Required to Dislodge Upper Denture With and Without Use of a Novel Denture Adhesive

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

A Bioequivalence Study of Advil PM Liqui-Gels Minis (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) Compared to the Current Marketed Advil PM Liqui-Gels (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) in Healthy Adult Subjects Under Fasted Conditions

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding

Ongoing Lung Decline With Age Intensified Response

Trial of Precision Medicine in Emergency Departments

Motivational Interviewing to Increase PrEP Uptake (MI-PrEP)

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses

Interpersonal Therapy-Based Treatment to Prevent Postpartum Depression in Adolescent Mothers

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT

The Role of an Attention Demanding Activity for Priming Motor Learning

Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

Neural Mechanisms of Spatial Representations Beyond the Self

Increasing Vaccine Uptake in Underresourced Public Housing Areas